Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Rhea-AI Summary
Neurocrine Biosciences (NBIX) has appointed Andrew Ratz, Ph.D. as Senior Vice President of Drug Development, Delivery and Device. Dr. Ratz will lead the transformation of Neurocrine's Chemistry, Manufacturing and Controls organization to support the company's expanding R&D portfolio.
Dr. Ratz joins Neurocrine following a 28-year tenure at Eli Lilly, where he contributed to developing and registering over 25 products across multiple therapeutic areas. His most recent role was Senior Vice President and Head of Drug Delivery, Device and Connected Solutions, where he led the integrated design of devices, drug-device combination products, and packaging systems. He previously served as Senior Director of Process Chemistry and Chemical Engineering and Head of Global Outsourcing for Lilly's small molecule portfolio.
Positive
- Appointment of seasoned executive with 28-year experience at Eli Lilly
- Track record of successful development and registration of 25+ products
- Expertise in drug delivery systems and device development strengthens R&D capabilities
Negative
- None.
News Market Reaction – NBIX
In the trading session that priced this news, NBIX gained 0.78%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Ratz joins Neurocrine after a 28-year career at Eli Lilly and Company, where he contributed to the development and successful registration of more than 25 products across multiple therapeutic areas and molecule modalities. Most recently, he served as Lilly's Senior Vice President and Head of the Drug Delivery, Device and Connected Solutions organization. He led the integrated design and development of devices, drug-device combination products, and packaging systems for both the biotech and small molecule portfolios. Prior to that, Dr. Ratz was Senior Director of Process Chemistry and Chemical Engineering and Head of Global Outsourcing for Lilly's small molecule portfolio.
"Andy brings unparalleled leadership and experience to Neurocrine's R&D team," Neurocrine Biosciences Chief Scientific Officer Jude Onyia, Ph.D., said. "He joins at a critical and exciting time for the company as we seek to discover and develop the next generation of treatments for patients with great needs."
"My love of science, coupled with a passion for helping people, has always driven my professional journey," Dr. Ratz said. "The opportunity to be part of Neurocrine, where innovation meets a commitment to improving lives, is truly inspiring. I am excited to contribute to the groundbreaking work being done here and to make a lasting impact on patients' lives through science and discovery."
Dr. Ratz received a Bachelor of Science degree in Chemistry from
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with
The NEUROCRINE BIOSCIENCES Logo Lockup and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/andrew-ratz-phd-joins-neurocrine-biosciences-as-senior-vice-president-of-drug-development-delivery-and-device-302358103.html
SOURCE Neurocrine Biosciences, Inc.